revolution medicines

revolution medicines

NASDAQ: RVMD

Chart

Detailed Quote

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Featured Articles and Interviews
Collage with hands holding shiny DNA molecule on blue background.

5 Biggest Biotechnology ETFs in 2026

Scientist pouring blue liquid from a test tube into a flask in a lab.

Biotech Market Forecast: Top Trends for Biotech in 2026

Press Releases

European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 

Revolution Medicines to Present Clinical Data from RAS Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

The Conversation (0)